Rain Therapeutics Doses First Patient in Phase 2 Basket Trial of Milademetan for MDM2-Amplified Advanced Solid Tumors (MANTRA-2)

Ads

You May Also Like

Aviragen Therapeutics to Host KOL Meeting on HRV Infections on October 13, 2016 in New York

ATLANTA, Oct. 10, 2016 (GLOBE NEWSWIRE) -- Aviragen Therapeutics, Inc. (NASDAQ:AVIR), a pharmaceutical company ...

Novartis announces Oncology head to retire

Basel, December 15, 2017 - Novartis announced today that Bruno Strigini, CEO Novartis Oncology ...

Delcath Announces Third Quarter Fiscal 2018 Financial Results

NEW YORK, Nov. 13, 2018 (GLOBE NEWSWIRE) -- Delcath Systems, Inc. (OTCQB: DCTH), an ...